Compare OPRX & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPRX | PYXS |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.7M | 243.5M |
| IPO Year | N/A | 2021 |
| Metric | OPRX | PYXS |
|---|---|---|
| Price | $12.35 | $1.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $14.83 | $6.75 |
| AVG Volume (30 Days) | 242.0K | ★ 1.7M |
| Earning Date | 11-06-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $109,506,000.00 | $2,820,000.00 |
| Revenue This Year | $19.77 | N/A |
| Revenue Next Year | $11.33 | N/A |
| P/E Ratio | $6,842.22 | ★ N/A |
| Revenue Growth | ★ 24.18 | N/A |
| 52 Week Low | $3.99 | $0.83 |
| 52 Week High | $22.25 | $5.55 |
| Indicator | OPRX | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 31.29 | 20.62 |
| Support Level | $12.66 | $1.03 |
| Resistance Level | $13.78 | $4.58 |
| Average True Range (ATR) | 0.60 | 0.29 |
| MACD | 0.01 | -0.32 |
| Stochastic Oscillator | 2.97 | 1.13 |
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.